tbuckley/cabot-search huggingface dataset:
Tolstoy in Medicine
Authors: Rola Khedraki
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States
Authors: Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Rory M Shallis, Nikolai A. Podoltsev, Jan Philipp Bewersdorf, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J Davidoff, Xiaomei Ma
Journal: Blood (2019)
Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation
Authors: Cindy Lynn Hickey, Haesook T. Kim, Vincent T. Ho, Sarah Nikiforow, Mahasweta Gooptu, John Koreth, Jerome Ritz, Rizwan Romee, Edwin P. Alyea, Robert J. Soiffer, Joseph H. Antin, Corey Cutler
Journal: Blood (2019)
Psychological origins of the Industrial Revolution: Why we need causal methods and historians
Authors: Johannes Haushofer
Journal: Behavioral and Brain Sciences (2019)

Abstract Did affluence lead to psychological changes such as reduced discounting, and did these changes facilitate the innovation associated with the Industrial Revolution? I argue that claims of this sort are best made when they can be supported by causal evidence and good psychological measurement. When we have neither identifying variation nor adequate measures, the toolbox of psychologists is not useful.
Family Visitation Policies in the ICU and Delirium
Authors: Philippe R. Bauer, Alejandro A. Rabinstein, Michael E. Wilson
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Study links air pollution to several new causes of hospital admissions
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Short term exposure to fine particulate matter in the air (known as PM2.5) is associated with several newly identified causes of hospital admissions, even at levels below international air quality guidelines, according to a new study.1

The paper, published in The BMJ , looked at the risks and costs of hospital admission associated with fine particulate matter. It found that exposure was linked to several prevalent but rarely studied causes of hospital admissions, such as septicemia, fluid and electrolyte disorders, acute and unspecified renal failure, and intestinal obstruction without hernia.

The researchers, from Harvard TH Chan School of Public Health, are now calling for the World Health Organization to revise its air quality guidelines in response.

WHO’s current air quality guideline for 24 hour average exposure …
Impact of chemistry and nanoformulation parameters on cellular uptake and airway distribution of RNA oligonucleotides
Authors: Erik Oude Blenke, Sunny Mahakena, Marcel Fens, Joep van den Dikkenberg, Maarten Holkers, Enrico Mastrobattista
Journal: Journal of Controlled Release (2019)

Small, synthetic oligonucleotides (ON) are of great interest as potential disease modifying drugs, mainly because of their ability to modulate previously undruggable target mutations. To date, therapeutic applications of ON are, however, limited by their physicochemical properties, including poor stability, rapid excretion and low intracellular access. In order to overcome some of these shortcomings, ON are generally formulated using nanoparticle (NP) delivery systems. Alternatively, the poor stability can be circumvented by including chemical modifications to the backbone or sugars of the ON. Some of these modifications also result in better intracellular target access of these otherwise membrane-impermeable macromolecules. Therefore, complex formulation of ON into NP in order to overcome the hurdle of intracellular access might not always be needed, especially in case of local delivery. In this study, the delivery and functionality of chemically modified ON in free form was compared to polymeric NP assisted delivery, measuring their effectivity and efficiency. For this reason, phosphorothioate (PS) backbone-modified 18-mer ON with either 2'OMe or 2'MOE-modifications were selected, capable of eliciting exon-skipping of an aberrant exon in fluorescence based in vitro and in vivo model systems. The NP consisted of poly(D,L-lactic,co-glycolic acid) and poly-β-amino-ester, previously demonstrated to successfully deliver nucleic acids via the pulmonary route. Several NP formulation parameters were tested in order to optimize the delivery of the ON, including ratio polymer:ON, NP size and concentration. The results reported here show clear differences between gymnotic and nanoparticle mediated ON delivery in terms of cellular uptake and local tissue distribution. In vitro, differences in exon-skipping efficiencies were observed with 2'OMe and 2'MOE ON either in free form or formulated in NP, with the striking observation that 2'OMe ON formulated in polymeric NP did not result in exon skipping. Gymnotic delivery of 2'MOE ON into the respiratory tract of mice resulted in functional delivery of exon-skipping ON into nasal epithelia and lungs as well as other downstream tissues and organs, pointing towards a gradual redistribution of locally delivered ONs, with limited but measurable systemic exposure. Conversely, NP-mediated delivery into the respiratory tract resulted in a more contained functional delivery at 10× lower ON doses compared to gymnotic delivery. Based on these findings we conclude that gymnotic delivery of 2'OMe or 2'MOE exon-skipping ON to the respiratory tract is effective, but that NP formulation might be advantageous in case spread of ON to non-target tissue can lead to undesired effects.
Comparison of Genetic Liability for Sleep Traits Among Individuals With Bipolar Disorder I or II and Control Participants
Authors: Katie J. S. Lewis, Alexander Richards, Robert Karlsson, Ganna Leonenko, Samuel E. Jones, Hannah J. Jones, Katherine Gordon-Smith, Liz Forty, Valentina Escott-Price, Michael J. Owen, Michael N. Weedon, Lisa Jones, Nick Craddock, Ian Jones, Mikael Landén, Michael C. O’Donovan, Arianna Di Florio
Journal: JAMA Psychiatry (2019)

Insomnia, hypersomnia, and an evening chronotype are common in individuals with bipolar disorder (BD), but whether this reflects shared genetic liability is unclear. Stratifying by BD subtypes could elucidate this association and inform sleep and BD research.To assess whether polygenic risk scores (PRSs) for sleep traits are associated with BD subtypes I and II.This case-control study was conducted in the United Kingdom and Sweden with participants with BD and control participants. Multinomial regression was used to assess whether PRSs for insomnia, daytime sleepiness, sleep duration, and chronotype are associated with BD subtypes compared with control participants. Affected individuals were recruited from the Bipolar Disorder Research Network. Control participants were recruited from the 1958 British Birth Cohort and the UK Blood Service. Analyses were repeated in an independent Swedish sample from August 2018 to July 2019. All participants were of European ancestry.Standardized PRSs derived using alleles from genome-wide association studies of insomnia, sleep duration, daytime sleepiness, and chronotype. These were adjusted for the first 10 population principal components, genotyping platforms, and sex.Association of PRSs with BD subtypes, determined by semistructured psychiatric interview and case notes.The main analysis included 4672 participants with BD (3132 female participants [67.0%]; 3404 with BD-I [72.9%]) and 5714 control participants (2812 female participants [49.2%]). Insomnia PRS was associated with increased risk of BD-II (relative risk [RR], 1.14 [95% CI, 1.07-1.21]; P = 8.26 × 10-5) but not BD-I (RR, 0.98 [95% CI, 0.94-1.03]; P = .409) relative to control participants. Sleep-duration PRS was associated with BD-I (RR, 1.10 [95% CI, 1.06-1.15]; P = 1.13 × 10-5) but not BD-II (RR, 0.99 [95% CI, 0.93-1.06]; P = .818). Associations between (1) insomnia PRS and BD-II and (2) sleep-duration PRS and BD-I were replicated in the Swedish sample of 4366 individuals with BD (2697 female participants [61.8%]; 2627 with BD-I [60.2%]) and 6091 control participants (3767 female participants [61.8%]). Chronotype and daytime-sleepiness PRS were not associated with BD subtypes.Per this analysis, BD subtypes differ in genetic liability to insomnia and hypersomnia, providing further evidence that the distinction between BD-I and BD-II has genetic validity. This distinction will be crucial in selecting participants for future research on the role of sleep disturbance in BD.
Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy
Authors: Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Farhad Ravandi, Jorge E. Cortes, Naval G. Daver, Koichi Takahashi, Courtney D. DiNardo, Elias Jabbour, Gautam M. Borthakur, Kiran Naqvi, Marina Y Konopleva, Sherry A. Pierce, Carlos E. Bueso-Ramos, Keyur P. Patel, Hagop M. Kantarjian, Guillermo Garcia-Manero, Tapan M. Kadia
Journal: Blood (2019)
Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Authors: Chiara F Magnani, Giuseppe Gaipa, Daniela Belotti, Giada Matera, Sarah Tettamanti, Benedetta Cabiati, Chiara Buracchi, Grazia Fazio, Silvia Zaninelli, Silvia Rigamonti, Stefania Cesana, Valentina Colombo, Giovanni Cazzaniga, Attilio Rovelli, Adriana Balduzzi, Sara Napolitano, Fabrizio Benedicenti, Eugenio Montini, Gian Maria Borleri, Silvia Ferrari, Giuseppe Gritti, Federico Lussana, Martino Introna, Alessandro Rambaldi, Giuseppe Dastoli, Andrea Biondi
Journal: Blood (2019)
It Takes Two (Genomes) to Cancer: Paired Viral and Host Transcriptome Analysis Provides New Insights about EBV Carcinogenicity
Authors: Sam M. Mbulaiteye, Ludmila Prokunina-Olsson
Journal: Cancer Research (2019)

Abstract The discovery of Epstein–Barr virus (EBV) in 1964 gave birth to the field of viral oncology. Despite significant scientific and clinical developments in research on several other viruses discovered and linked to cancer risk much later, our understanding of EBV as a carcinogen and a possible target for therapeutic interventions remains limited. In this issue of Cancer Research, Chakravorty and colleagues present results of massive reanalysis of public RNA-sequencing data for 291 control and 1,051 tumor samples representing 15 cancer types. Their paired analysis of the viral and host transcriptome sheds light on mechanisms of EBV carcinogenicity and provides new leads for translational applications. See related article by Chakravorty et al., p. 6010
Efficacy and Safety of Endoscopic Resection of Sessile Serrated Polyps 10 mm or Larger: A Systematic Review and Meta-Analysis
Authors: Viveksandeep Thoguluva Chandrasekar, Muhammad Aziz, Harsh K. Patel, Naaz Sidhu, Abhiram Duvvuri, ChandraShekhar Dasari, Kevin F. Kennedy, Ashwini Ashwath, Marco Spadaccini, Madhav Desai, Ramprasad Jegadeesan, Anjana Sathyamurthy, Prashanth Vennalaganti, Divyanshoo Kohli, Cesare Hassan, Maria Pellise, Alessandro Repici, Prateek Sharma, Michael J. Bourke
Journal: Clinical Gastroenterology and Hepatology (2019)
High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia
Authors: Emanuela M. Ghia, Laura Z. Rassenti, Michael Y. Choi, Elvin Chu, George F. Widhopf II, Thomas J. Kipps
Journal: Blood (2019)
Developing mechanically robust, triazole-zwitterionic hydrogels to mitigate foreign body response (FBR) for islet encapsulation
Authors: Qingsheng Liu, Alan Chiu, Longhai Wang, Duo An, Wenchen Li, Esther Y. Chen, Yu Zhang, Yehudah Pardo, Sean P. McDonough, Lingyun Liu, Wendy F. Liu, Jing Chen, Minglin Ma
Journal: Biomaterials (2019)
Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT)
Authors: Maurizio Miano, Dirk-Jan Eikema, Josu de la Fuente, Paul Bosman, Ardeshir Ghavamzadeh, Frans Smiers, Henrik Sengeløv, Akif Yesilipek, Renata Formankova, Peter Bader, Miguel Ángel Díaz Pérez, Yves Bertrand, Charlotte Niemeyer, Dominique Bron, Marc Ansari, Tatiana A Bykova, Edoardo Lanino, Attilio Rovelli, Jolanta Gozdzik, Tariq Mahmood Satti, Ivana Bodova, Matthias Wölfl, Vanderson G. Rocha, Karin Mellgren, Jelena Rascon, Andrzej Lange, Roland Meisel, Yves Beguin, Yasmina Mozo, Gergely Kriván, Anne Sirvent, Benedicte Bruno, Daniela Onofrillo, Antonio M. Risitano, Régis Peffault de Latour, Carlo Dufour
Journal: Blood (2019)
Risk of malignancy in patients treated for systemic necrotising vasculitis
Authors: Antoine Lafarge, Adrien Joseph, Christian Pagnoux, Xavier Puechal, Pacal Cohen, Maxime Samson, Mohamed Hamidou, Alexandre Karras, Matthieu Groh, Thomas Quemeneur, Camillo Ribi, Luc Mouthon, Loic Guillevin, Benjamin Terrier
Journal: Annals of the Rheumatic Diseases (2019)

Reduction in cyclophosphamide cumulative dose and introduction of newer immunosuppressive drugs may reduce the malignant burden of systemic necrotising vasculitis (SNV).1 2 This study aimed to describe malignancies recorded in five randomised controlled trials in SNV conducted by the French Vasculitis Study Group and to identify predictive factors.

CHUSPAN, CHUSPAN 2, WEGENT, CORTAGE and MAINRITSAN trials evaluated different therapeutic strategies, summarised in online supplementary table S1, for the treatment of newly diagnosed or relapsing SNV. Informations regarding methods and references are provided in the online supplementary materials. The primary endpoint was the occurrence of malignancy.### Supplementary data

[annrheumdis-2019-216452supp001.pdf] 

A total of 733 patients included between 1993 and 2012 were pooled. Baseline characteristics of the population are summarised in table 1. During a 4485.9 person-years (PY) observation period, 39 (5.3%) patients developed malignancies (869.5 per 100 000 PY), including solid cancers in 34 (4.6%) cases (757.9 per 100000 PY) and haematological malignancies in 5 …
Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)
Authors: Michelle J. Cox, Fabrice Lucien-Matteoni, Reona Sakemura, Justin C. Boysen, Yohan Kim, Michael J. Hansen, Claudia Manriquez Roman, Erin E. Tapper, Sydney B. Crotts, Kendall J. Schick, Mehrdad Hefazi, Paulina Roman Moreno, Michael W. Ruff, Sameer A. Parikh, Neil E. Kay, Saad S. Kenderian
Journal: Blood (2019)
Abstract 359: The Effect of BDNF on the Neuroprotection of Win55,212-2 Pharmacological Hypothermia After CPR in a Rat Cardiac Arrest Model
Authors: Fengqing Song, Tao YU, Xiangshao Fang, Longyuan Jiang, Zhengfei Yang, Wanchun Tang
Journal: Circulation (2019)

Introduction: Studies have demonstrated that Win55,212-2 induced pharmacological hypothermia and protected the neurological function after cardiopulmonary resuscitation (CPR) in a rat cardiac arrest (CA) model. However, the mechanism is still unclear. In this study, we hypothesized brain derived neurotrophic factor (BDNF) was involved in this mechanism. Methods: CA was induced by transoesophageal ventricular pacing in SD rats. 5min after onset of CA, CPR was started. After 30 min of ROSC, 30 animals were randomized into either Win55, 212-2 group (animals in drug groups were received continuous intravenous infusion of Win55,212-2 with 1 mg/kg/h for 4 h) or Normothermia group (animals were received 5% DMSO). Rats in normothermia group were maintained at 37°C with warming lamp though the whole experiment. Rats in drug group were warmed to 37°C increasingly after 4h of Win55,212-2 treatment. Brains of five animals in each group were harvested for detecting BDNF by RT-PCT and Westen blot at 24 h after ROSC respectively. Results: Temperatures of animals in Win55,212-2 group decreased to 34°C in 4 hours after ROSC, and the survival of which were longer than that of the control group. The expression of BDNF was significantly higher in the Win55, 212-2 group than that of control group. Conclusions: BDNF paticipated the neuroprotection of Win 55,212-2 after CPR in a rat CA model.
Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Authors: Y. Bai, N. Xu, X. Yuan, B. Wang, E. Li, X. Li, Y. Li, X. Wang, S. Yang, J. Xu
Journal: Annals of Oncology (2019)
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331
Authors: Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Michael J. Borowitz, Elizabeth A. Raetz, Gerhard Zugmaier, Elad Sharon, Lia Gore, James A. Whitlock, Michael A. Pulsipher, Stephen P. Hunger, Mignon L. Loh
Journal: Blood (2019)
Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure
Authors: Orly Vardeny, Brian Claggett, Muthiah Vaduganathan, Iris Beldhuis, Jean Rouleau, Eileen O’Meara, Inder S. Anand, Sanjiv J. Shah, Nancy K. Sweitzer, James C. Fang, Akshay S. Desai, Eldrin F. Lewis, Bertram Pitt, Marc A. Pfeffer, Scott D. Solomon
Journal: JACC Heart Failure (2019)
Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232
Authors: Michael J. Burke, Meenakshi Devidas, Zhiguo Chen, Wanda Salzer, Elizabeth A. Raetz, Karen R. Rabin, Nyla A. Heerema, Andrew J. Carroll, Julie M. Gastier Foster, Michael J. Borowitz, Brent L Wood, Naomi Winick, William Carroll, Stephen P. Hunger, Mignon L. Loh, Eric Larsen
Journal: Blood (2019)
The intragraft vascularized bone marrow component plays a critical role in tolerance induction after reconstructive transplantation
Authors: Cheng-Hung Lin, Madonna R. Anggelia, Hui-Yun Cheng, Aline Yen Ling Wang, Wen-Yu Chuang, Chih-Hung Lin, W. P. Andrew Lee, Fu-Chan Wei, Gerald Brandacher
Journal: Cellular and Molecular Immunology (2019)

Abstract The role of the vascularized bone marrow component as a continuous source of donor-derived hematopoietic stem cells that facilitate tolerance induction of vascularized composite allografts is not completely understood. In this study, vascularized composite tissue allograft transplantation outcomes between recipients receiving either conventional bone marrow transplantation (CBMT) or vascularized bone marrow (VBM) transplantation from Balb/c (H2d) to C57BL/6 (H2b) mice were compared. Either high- or low-dose CBMT (1.5 × 10 8 or 3 × 10 7 bone marrow cells, respectively) was applied. In addition, recipients were treated with costimulation blockade (1 mg anti-CD154 and 0.5 mg CTLA4Ig on postoperative days 0 and 2, respectively) and short-term rapamycin (3 mg/kg/day for the first posttransplant week and then every other day for another 3 weeks). Similar to high-dose conventional bone marrow transplantation, 5/6 animals in the vascularized bone marrow group demonstrated long-term allograft survival (&gt;120 days). In contrast, significantly shorter median survival was noted in the low-dose CBMT group (~64 days). Consistently high chimerism levels were observed in the VBM transplantation group. Notably, low levels of circulating CD4 + and CD8 + T cells and a higher ratio of Treg to Teff cells were maintained in VBM transplantation and high-dose CBMT recipients (&gt;30 days) but not in low-dose VBM transplant recipients. Donor-specific hyporesponsiveness was shown in tolerant recipients in vitro. Removal of the vascularized bone marrow component after secondary donor-specific skin transplantation did not affect either primary allograft or secondary skin graft survival.
Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge
Authors: Haiyan Zhao, Lily Xu, Robin Bombardi, Rachel Nargi, Zengqin Deng, John M. Errico, Christopher A. Nelson, Kimberly A. Dowd, Theodore C. Pierson, James E. Crowe, Michael S. Diamond, Daved H. Fremont
Journal: The Journal of Experimental Medicine (2019)

We previously generated a panel of human monoclonal antibodies (mAbs) against Zika virus (ZIKV) and identified one, ZIKV-116, that shares germline usage with mAbs identified in multiple donors. Here we show that ZIKV-116 interferes with ZIKV infection at a post-cellular attachment step by blocking viral fusion with host membranes. ZIKV-116 recognizes the lateral ridge of envelope protein domain III, with one critical residue varying between the Asian and African strains responsible for differential binding affinity and neutralization potency (E393D). ZIKV-116 also binds to and cross-neutralizes some dengue virus serotype 1 (DENV1) strains, with genotype-dependent inhibition explained by variation in a domain II residue (R204K) that potentially modulates exposure of the distally located, partially cryptic epitope. The V-J reverted germline configuration of ZIKV-116 preferentially binds to and neutralizes an Asian ZIKV strain, suggesting that this epitope may optimally induce related B cell clonotypes. Overall, these studies provide a structural and molecular mechanism for a cross-reactive mAb that uniquely neutralizes ZIKV and DENV1.